1134803-18-1
Chemical Structure
Imatinib-d3 hydrochloride
Synonym(s): STI571-d3 hydrochloride; CGP-57148B-d3 hydrochloride
- CAS No.: 1134803-18-1
- Formula:C29H28D3N7O
- Molecular Weight:496.62
IUPAC Name: N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-(methyl-d3)piperazin-1-yl)methyl)benzamide
InChIKey: KTUFNOKKBVMGRW-BMSJAHLVSA-N
SMILES: O=C(C1=CC=C(C=C1)CN2CCN(CC2)C([2H])([2H])[2H])NC3=CC=C(C)C(NC4=NC=CC(C5=CN=CC=C5)=N4)=C3
Biological Activity: Imatinib-d3 (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Imatinib-d3 hydrochloride | 95.19% | Imatinib-d3 (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imatinib (Standard) | 99.74% | Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imatinib-d4 | 99.82% | Imatinib-d4 (STI571-d4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imatinib-13C,d3 | Imatinib-13C,d3 (STI571-13C,d3) is 13C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imatinib-d8 | 99.88% | Imatinib-d8 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imatinib | 99.95% | Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
